Our Network

Immuno-oncology has grown exponentially over the last decade and is transforming outcomes for patients.

Real-world data from INFORM study demonstrate increased risk of severe COVID-19
outcomes among all individuals with immunocompromising conditions
 and highlight need for additional protection.

FluMist Quadrivalent data support the potential for a self-administered influenza vaccine to expand access to an important tool for prevention.

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, 20 to 24 October 2023.

Cell therapy in oncology has been spearheaded by the development of therapeutic chimeric antigen receptor (CAR)‑T cells, created by isolating and modifying a patient’s T cells to target their cancer.

Clinically meaningful improvements in glycaemic control among patients aged 10-17 years compared to placebo. Prevalence of type 2 diabetes in children continues to increase, yet limited oral treatment options are available. 

Results from the largest proteogenomics study to date could transform how we, and others, approach drug discovery. After analysing over 50,000 human exomes from the UK Biobank, we uncovered links between rare protein-coding genetic variants and nearly 3,000 plasma proteins.
The findings from this research allow us to better understand the impact that certain genes and proteins have on disease.

First publication from NEURO-TTRansform trial in the treatment of patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Consistent and sustained benefit on all co-primary and secondary endpoints across patients with a diverse range of disease characteristics

The rapid and continued evolution of digital technology has enabled new digital healthcare solutions for clinical trials; this has the potential to transform clinical study design, the experience of patients and trial site teams, improve clinical outcomes, reduce timelines and burden for participants and improve environmental sustainability.